The purpose of this post-marketing surveillance is to investigate and confirm the type and incidence of newly identified adverse events and any other factors affecting safety and efficacy of Onglyza® so that the regulatory authority can manage the marketing approval properly.

Inclusion Criteria:

• Female and male patients who are at least 18 years of age
• Patients with diagnosis of T2DM initiating Onglyza® treatment within the approved indications in Korea

Exclusion Criteria:

• Indication which is not approved for Onglyza® in Korea
• Patients with contraindication for the use of Onglyza® (as clarified in Korean label)

Patients with diagnosis of type 2 diabetes mellitus initiating Onglyza® treatment within the approved indications will be enrolled